Description and Brand Names
Información sobre medicamentos proporcionada por: IBM Micromedex
Umbralisib is used to treat marginal zone lymphoma (MZL) that has come back (relapsed) or did not respond to the treatment (refractory) in patients who have received at least one previous treatment (eg, anti-CD20-based treatment). It is also used to treat follicular lymphoma (FL) that has come back or did not respond to treatment in patients who have received at least 3 previous treatments.
This medicine is available only with your doctor's prescription.
This medicine was withdrawn from the U.S. market on June 1, 2022, due to safety concerns.